[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 2,900,000 ordinary shares under the second tranche of its share buyback programme. After settlement, the company’s registered share capital is 8,956,321,411 ordinary shares of £0.01 each, with 3,880,205 held as treasury shares, leaving 8,952,441,206 ordinary shares with voting rights. The company provided a link to a full breakdown of individual trades and noted the announcement does not constitute an offer for securities. The buyback transaction was executed on the London Stock Exchange and details are posted on the company website.

Insights

Financial Analyst

TL;DR: Completed tranche of share buyback reduced outstanding voting shares modestly.

The company executed and cancelled 2.9 million shares as part of a previously announced repurchase programme, updating post-settlement share counts. This action reduces the number of ordinary shares with voting rights to 8,952,441,206 and increases treasury share holdings to 3,880,205. The filing supplies a trade-level breakdown link, ensuring transparency on execution. No financial impact figures (cash spent, percentage of market cap or programme size remaining) are disclosed in this notice, limiting assessment of materiality.

Corporate Governance Expert

TL;DR: Share cancellation is a standard capital management step with governance transparency provided.

The announcement clearly states the cancellation and updated voting share count, which shareholders can use for disclosure threshold calculations under FCA rules. Publication of the full trade breakdown and posting on the investor website aligns with regulatory transparency expectations. The notice does not disclose board rationale, funding source, or remaining programme details, so governance implications are limited to the administrative update provided.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	03 September 2025- “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

03 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,900,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	02 September 2025	02 September 2025	02 September 2025
Number of Shares purchased:	2,900,000	-	-
Highest price paid per Share (p):	365.0000	-	-
Lowest price paid per Share (p):	359.5000	-	-
Volume weighted average price paid per Share (p):	363.7313	-	-

Following the settlement of the above, the Company's registered share capital is 8,956,321,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,952,441,206 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7269X_1-2025-9-2.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 03, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLN) repurchase?

Haleon repurchased and cancelled 2,900,000 ordinary shares of £0.01 each under the second tranche of its buyback programme.

How many Haleon shares are outstanding with voting rights after the buyback?

After settlement, there are 8,952,441,206 ordinary shares with voting rights.

How many Haleon shares are held as treasury shares now?

The company holds 3,880,205 treasury shares following the transaction.

Where can I find the detailed trade breakdown for the repurchase?

A full breakdown of individual trades is available at the provided regulatory link and on www.haleon.com/investors.

Does this announcement include the total cash spent on the buyback?

No. The filing does not disclose the aggregate cash amount spent or what percentage of the buyback programme remains.